The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes of frontline GemFLP in advanced urachal and non-urachal adenocarcinomas of the urinary tract: The MD Anderson Cancer Center (MDACC) experience.
 
Mohammad Jad Moussa
No Relationships to Disclose
 
Adrienne H. Chen
No Relationships to Disclose
 
Allison K. Grana
No Relationships to Disclose
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; AstraZeneca; crispr therapeutics; Infinity Pharmaceuticals; Janssen; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca
 
Amishi Yogesh Shah
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Exelixis; Pfizer/EMD Serono
Research Funding - 4D Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst)
 
Paul Gettys Corn
No Relationships to Disclose
 
Nizar M. Tannir
Stock and Other Ownership Interests - Amgen; Arcturus Therapeutics; Arcus Biosciences; BioCryst; Corvus Pharmaceuticals; First Trust Amex Biotech (FBT); Johnson & Johnson/Janssen; Merck; Nuvation Bio; Revolution Medicines; Spdr S&P Pharmaceuticals ETF; Surface Oncology; Vanguard Health Care; Xencor
Honoraria - AstraZeneca/Merck; Bristol-Myers Squibb; Eisai; Exelixis; Intellisphere; Merck Sharp & Dohme; Nektar; Neoleukin Therapeutics; Oncorena
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Merck Sharp & Dohme; Nektar; Oncorena
Research Funding - Arrowhead Pharmaceuticals (Inst); Bristol Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Nektar (Inst); Novartis (Inst)
 
Sangeeta Goswami
No Relationships to Disclose
 
Jianbo Wang
No Relationships to Disclose
 
John C. Araujo
No Relationships to Disclose
 
Ashish M. Kamat
Honoraria - AstraZeneca (I); Tesaro (I)
Consulting or Advisory Role - Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; Biological Dynamics; Bristol-Myers Squibb; CG Oncology; Cystotech; Eisai; EnGeneIC; FerGene; Imagin Medical; Imvax; Incyte; Janssen; Medac; Merck; Nonagen Bioscience; Pfizer; Photocure; Protara Therapeutics; Roche; Seagen; Sesen Bio; Theralase; TMC Innovation; Urogen pharma; US Biotest
Research Funding - Adolor; Bristol-Myers Squibb; FKD Therapies; Heat Biologics; Janssen/Taris; Merck; NIH; Patient-Centered Outcomes Research Institute (PCORI); Photocure; Seagen; SWOG; Taris BioMedical; The Leo & Anne Albert Institute for Bladder Cancer Care and Research (AIBCCR)
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - European Urology Oncology; International Bladder Cancer Group (IBCG); International Bladder Cancer Network; Journal of Urology; UroToday
 
Neema Navai
No Relationships to Disclose
 
Curtis Alvin Pettaway
Consulting or Advisory Role - Wolters Kluwer
 
Mehrad Adibi
No Relationships to Disclose
 
Bogdan Czerniak
No Relationships to Disclose
 
Charles C. Guo
No Relationships to Disclose
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; Bavarian Nordic; Bristol-Myers Squibb; G1 Therapeutics; Genentech; Gilead Sciences; Ideeya Biosciences; Immunomedics; Janssen; Loxo; Merck; Mirati Therapeutics; NCCN; Nektar; Seagen; Taiho Pharmaceutical
Research Funding - Basilea (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); NIH (Inst)
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Matthew T Campbell
Honoraria - Axdev; Curio Science; Exelixis; Seagen; Targeted Oncology
Consulting or Advisory Role - Exelixis
Research Funding - Apricity Health (Inst); Aravive (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - AVEO; Exelixis; SeaGen
 
Omar Alhalabi
Consulting or Advisory Role - Cardinal Health; Seagen; Silverback Therapeutics
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Ikena Oncology (Inst)